Xtant Medical Holdings, Inc. XTNT
0.28 USD -0.01 (-2.49%)
Nov 9, 2026, 10:35 AM EST
0.2763 Day range 0.299
0.27 52-week range 0.84
- YTD
- -63.82%
- 1 year
- -62.37%
News
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com LUCID CAPITAL MARKETS Initiates Coverage On Xtant Medical Holdings with Buy Rating, Announces Price Target of $1 LUCID CAPITAL MARKETS analyst Alex Nowark initiates coverage on Xtant Medical Holdings (AMEX:XTNT) with a Buy rating and announces Price Target of $1.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Aardvark Therapeutics (NASDAQ:AARD) shares increased by 8.5% to $6.28 during Friday's after-market session. The market value of their outstanding shares is at $144.8 million. TransCode…
- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 24.6% to $6.42 during Friday's regular session. The company's market cap stands at $10.3 million. Aethlon Medical (NASDAQ:AEMD) shares moved…
- benzinga.com Xtant Medical Enters Exclusive Partnership With Henry Schein's Biohorizons To Distribute The Company's Allogeneic Growth Factor Technology Under The Prolifica Private Brand The agreement establishes BioHorizons as the exclusive distributor of Xtant's allogeneic growth factor technology into the dental and oral-maxillofacial procedure markets in the United States and…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session Gainers Neuronetics (NASDAQ:STIM) shares moved upwards by 34.1% to $2.91 during Tuesday's regular session. The market value of their outstanding shares is at $151.0 million. As per the press release,…
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers Mereo BioPharma Group (NASDAQ:MREO) stock increased by 21.7% to $0.33 during Tuesday's pre-market session. The market value of their outstanding shares is at $43.4 million. Organigram Global…
benzinga.com Xtant Medical Hldgs Q2 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $23.031M Miss $24.875M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 250 percent decrease over earnings of…
benzinga.com Xtant Medical Hldgs Lowers FY2026 Sales Guidance from $101.000M-$105.000M to $99.000M-$103.000M vs $102.058M Est Xtant Medical Hldgs (AMEX:XTNT) lowers FY2026 sales outlook from $101.000 million-$105.000 million to $99.000 million-$103.000 million vs $102.058 million estimate.- benzinga.com BTIG Reiterates Buy on Xtant Medical Holdings, Maintains $1 Price Target BTIG analyst Ryan Zimmerman reiterates Xtant Medical Holdings (AMEX:XTNT) with a Buy and maintains $1 price target.
- benzinga.com Xtant Medical Hldgs Q1 2026 Earnings Call Transcript
benzinga.com Earnings Scheduled For May 13, 2026 
benzinga.com Xtant Medical Raises FY2026 Sales Guidance from $95.000M-$99.000M to $101.000M-$105.000M vs $96.725M Est 2026 Financial GuidanceThe Company is today increasing its full-year 2026 revenue guidance to a range of $101 million to $105 million, from $95 million to $99 million previously, to reflect the…
benzinga.com Xtant Medical Hldgs Q1 EPS $(0.02), Inline, Sales $20.884M Beat $20.164M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.02) per share which met the analyst consensus estimate. The company reported quarterly sales of $20.884 million which beat the analyst…- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com Xtant Medical Holdings Acquires Exclusive U.S. Distribution Rights To Dilon Technologies' HEMOBLAST Bellows Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, and Dilon Technologies, Inc., a medical…
- benzinga.com BTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1 BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $1.5 to $1.
benzinga.com Xtant Medical Hldgs Sees FY2026 Sales $95.000M-$99.000M vs $110.100M Est Xtant Medical Hldgs (AMEX:XTNT) sees FY2026 sales of $95.000 million-$99.000 million vs $110.100 million analyst estimate.- benzinga.com Earnings Scheduled For March 31, 2026
benzinga.com Xtant Medical Hldgs Q4 Sales $32.357M Beat $30.750M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly sales of $32.357 million which beat the analyst consensus estimate of $30.750 million by 5.23 percent. This is a 2.68 percent increase over sales of…- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Xtant Medical Receives $10.7M Related To Companion Spine's Purchase Of Xtant's Coflex Assets And Paradigm OUS Businesses, Bringing Total Price For Two Divestitures To $21.4M Xtant received $10.7 million in satisfaction of unsecured promissory note issued to Xtant by Companion Spine plus related working capital adjustmentsBELGRADE, Mont., March 2, 2026 /PRNewswire/ --…
benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session - benzinga.com BTIG Maintains Buy on Xtant Medical Hldgs, Lowers Price Target to $1.5 BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and lowers the price target from $2 to $1.5.
benzinga.com Xtant Medical Hldgs Affirms FY2025 Sales Guidance of $131.000M-$135.000M vs $129.950M Est Xtant Medical Hldgs (AMEX:XTNT) affirms FY2025 sales outlook from $131.000 million-$135.000 million to $131.000 million-$135.000 million vs $129.950 million estimate.- benzinga.com Xtant Medical Hldgs Q3 EPS $0.01 Beats $(0.01) Estimate, Sales $33.300M Beat $32.700M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 125 percent increase over losses of…
benzinga.com Earnings Preview For Xtant Medical Hldgs - benzinga.com Xtant Medical Hldgs Raises FY2025 Sales Guidance from $127.000M-$131.000M to $131.000M-$135.000M vs $129.550M Est Xtant Medical Hldgs (AMEX:XTNT) raises FY2025 sales outlook from $127.000 million-$131.000 million to $131.000 million-$135.000 million vs $129.550 million estimate.
- benzinga.com Xtant Medical Hldgs Q2 EPS $0.02 Beats $(0.01) Estimate, Sales $30.436M Miss $31.350M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.01) by 300 percent. This is a 166.67 percent increase over losses of…
- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Earnings Preview For Xtant Medical Hldgs
- benzinga.com Xtant Medical Holdings, Announces The Company Has Entered Into Agreements To Sell Certain Coflex And Cofix Interlaminar Stabilization Implant Assets And All OUS Entities Of Paradigm Spine GmbH To Companion Spine LLC. Proceeds Of Transaction Total $19.2M Xtant Medical Holdings, Inc. (NYSE:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic, and woundcare disorders, today announced that the…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com Xtant Medical Hldgs Raises FY2025 Sales Guidance from $126.00M-$130.00M to $127.00M-$131.00M vs $128.35M Est Xtant Medical Hldgs (AMEX:XTNT) raises FY2025 sales outlook from $126.00 million-$130.00 million to $127.00 million-$131.00 million vs $128.35 million estimate.
- benzinga.com Xtant Medical Hldgs Q1 Sales $32.90M Beat $31.20M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly sales of $32.90 million which beat the analyst consensus estimate of $31.20 million by 5.46 percent. This is a 18.05 percent increase over sales of…
- benzinga.com Earnings Scheduled For May 12, 2025
- benzinga.com A Glimpse of Xtant Medical Hldgs's Earnings Potential
- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
- benzinga.com Xtant Medical Hldgs Sees FY2025 Revenue of $126.000M-$130.000M vs $132.85M Est Xtant Medical Hldgs (AMEX:XTNT) sees FY2025 sales of $126.000 million-$130.000 million vs $132.85 million analyst estimate.
- benzinga.com Xtant Medical Hldgs Q4 EPS $(0.02) Misses $(0.01) Estimate, Sales $31.51M Miss $31.80M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $(0.01) by 100 percent. This is a 33.33 percent increase over losses of…
- benzinga.com Earnings Scheduled For March 6, 2025
- benzinga.com Xtant Medical Hldgs Affirms FY2024 Sales Guidance from $116.00M-120.00M to $116.00M-$120.00M Xtant Medical Hldgs (AMEX:XTNT) affirms FY2024 sales outlook from $116.00 million-120.00 million to $116.00 million-120.00 million.
- benzinga.com Xtant Medical Hldgs Q3 2024 GAAP EPS $(0.04) Misses $(0.03) Estimate, Sales $27.937M Miss $29.300M Estimate Xtant Medical Hldgs (AMEX:XTNT) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $(0.03) by 33.33 percent. The company reported quarterly sales of $27.937…
- benzinga.com Earnings Scheduled For November 12, 2024
- benzinga.com Xtant Medical Hldgs's Earnings Outlook
- benzinga.com Xtant Medical Expands Product Portfolio With The Launch Of The Cortera Posterior Fixation System New System Enhances Surgical Efficiency and Provides Versatile Solutions for Complex Spine ProceduresBELGRADE, MT / ACCESSWIRE / September 23, 2024 / Xtant Medical Holdings, Inc. (NYSE:XTNT), a…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com BTIG Maintains Buy on Xtant Medical Hldgs, Raises Price Target to $3 BTIG analyst Ryan Zimmerman maintains Xtant Medical Hldgs (AMEX:XTNT) with a Buy and raises the price target from $2 to $3.